RNA modifications are indispensable for the translation machinery to provide accurate and efficient protein synthesis. Whereas the importance of transfer RNA (tRNA) and ribosomal RNA (rRNA) modifications has been well described and is unquestioned for decades, the significance of internal messenger RNA (mRNA) modifications has only recently been revealed. Novel experimental methods have enabled the identification of thousands of modified sites within the untranslated and translated regions of mRNAs. Thus far, N^6^-methyladenosine (m^6^A), pseudouridine (Ψ), 5-methylcytosine (m^5^C) and N^1^-methyladenosine (m^1^A) were identified in eukaryal, and to some extent in prokaryal mRNAs. Several of the functions of these mRNA modifications have previously been reported, but many aspects remain elusive. Modifications can be important factors for the direct regulation of protein synthesis. The potential diversification of genomic information and regulation of RNA expression through editing and modifying mRNAs is versatile and many questions need to be addressed to completely elucidate the role of mRNA modifications.

Herein, we summarize and highlight some recent findings on various co- and post-transcriptional modifications, describing the impact of these processes on gene expression, with emphasis on protein synthesis. © 2016 The Authors. WIREs RNA published by Wiley Periodicals, Inc.

**INTRODUCTION**

Messenger RNA (mRNA) translation is a central process in every living organism. The assembly and operation of the translation machinery are very costly and can consume up to 40% of the cellular energy. Therefore, protein synthesis needs to be strictly regulated in many aspects. The regulation of translation is typically associated with the necessity of regulatory proteins and regulatory non-coding RNAs (ncRNAs). However, equally important for the translation process are nucleotide modifications, which are present in all involved classes of RNA. Ribosomal RNAs (rRNAs), transfer RNAs (tRNAs) and mRNAs are co- or post-transcriptionally modified. Whereas the precise function of many of these nucleotide derivatives remains enigmatic, it has become evident that many of those are important factors for numerous biological processes, such as ribosome assembly, mRNA stability, RNA folding, and accurate and efficient protein biosynthesis, to name a few. More than 100 different types of RNA modifications in almost every class of non-coding and coding RNAs have been reported.

Most of the modifications described thus far have been identified in tRNAs. These modifications strongly vary in chemical and structural complexity and are necessary for the proper folding and function of tRNAs. Several reported modifications are crucial for the correct geometry of the anticodon loop and therefore affect the decoding process. Other modifications are mandatory for the aminoaacylation of the respective tRNA body. However, many tRNA modifications are assumed to have no or only a minor impact. Considering the effort necessary to specifically introduce modifications, the functional
role of these modifications during the ‘life cycle’ of a tRNA might not yet be revealed.

The second class of RNA that requires modification for functionality is ribosomal RNA. The number of rRNA modifications identified in prokaryotic organisms is rather small (23 modifications in *Thermus thermophilus* and 35 modifications in *Escherichia coli*), compared with eukaryotes (~100 modifications in yeast and 200 modifications in vertebrates). Most of the modified nucleotides are located near the peptidyl transferase center in the large ribosomal subunit and the decoding site in the small ribosomal subunit. The function of most modifications is obscure. Whereas only deletions of whole clusters of rRNA modifications severely impair the translation capability of ribosomes, the loss of single RNA nucleotide derivatives has a rather small effect on the basic capability of ribosomes, the loss of single RNA nucleotide derivatives has a rather small effect on the basic steps of translation. Even ribosomes carrying rRNAs without any post-transcriptional modifications are capable of synthesizing full-length proteins *in vitro*, suggesting that these RNA modifications are not fundamental for all basic steps of protein biosynthesis. However, some methylated nucleotides have been implicated in fine-tuning translation initiation and decoding fidelity, and several pseudouridines (Ψs) are pivotal for forming the intersubunit bridge B2a.

Still many questions concerning the role of rRNA modifications during protein synthesis or ribosome assembly remain unanswered. Although the co- and post-transcriptional modification of mRNAs had been described decades ago, recent computational approaches and high-throughput RNA sequencing techniques have revealed thousands of novel modification sites within coding sequences and untranslated regions (UTRs) of mRNAs. These findings have boosted interest in the types and potential roles for mRNA modifications during gene expression.

Post-transcriptional modifications of RNA can be historically classified into two groups: edited RNA and modified RNA. RNA editing is usually understood as posttranscriptional RNA processing (except capping, splicing and polyadenylation) that changes the RNA nucleotide sequence compared with the genetically encoded sequence. This processing can be achieved through the insertion/deletion of nucleotides or deamination of nucleobases, generating either standard nucleotides or the rare nucleotide inosine (I). mRNA modifications, however, are considered alterations in the chemical composition or conformation of a nucleotide that potentially influences the function or stability of the transcript. The definition of edited or modified RNAs should not be taken too strictly, as these terms are often context-dependent.

In the 1970s, internal N6-methyladenosine (m6A) and low levels of 5-methylcytosin (m5C) were revealed in mRNAs of eukaryotic cells. Since then, other RNA nucleotide derivatives, such as are Ψ, N1-methyladenosine (m1A),21,22 have been reported within mRNAs. Whereas most of the nucleotide derivatives were found in eukaryotic organisms, some derivatives were also abundant in prokaryotic mRNAs.18,25

The modification and editing of mRNAs are essential processes that influence and regulate gene expression at the post-transcriptional level. In this review, we summarized and highlighted important findings in this field. mRNA modifications are involved in many aspects of mRNA processing, stability, folding and translation. We also specifically focus on the involvement of mRNA modifications in protein synthesis, and discuss the impact of these processes on gene expression.

### mRNA Editing Diversifies Protein Synthesis

#### Nucleotide Insertions and Deletions

In 1986 Benne and co-workers first described striking discrepancies between the DNA sequence of a gene and the RNA sequence of the corresponding transcript. The authors revealed four uridines within the mRNA of the mitochondrial oxidase II subunits in trypanosomes that were not genetically encoded. This observation implied that nucleotides are inserted into the mRNA during or after transcription, thereby repairing a genomic frameshift site. In subsequent studies, more examples of U insertions and deletions were identified, and it became evident that these editing processes are characteristic for the order of kinetoplastid protozoa. Indeed, the post-transcriptional insertion of uridines into the transcripts of certain mitochondrial genes can be rather extensive, making it challenging to identify the corresponding DNA sequence.

In addition, guanosines (Gs) and adenosines (As) are also inserted into mRNAs of the Paramyxoviruses and the Ebola viruses, respectively. The mitochondrial mRNAs of *Physarum polycephalum* harbor co-transcriptionally inserted cytosines (Cs) and even various dinucleotides (AA, CU, GU, GC and UA). Independent of the number or type of post-transcriptionally inserted/deleted nucleotides, the genetic information can be revised co- and post-transcriptionally, thereby generating open reading frames (ORFs) through the creation of start and stop codons. In addition, the reading frame can be
changed and the sequence information of the mRNA altered, thereby significantly impacting gene expression (Figure 1).

C-to-U Editing

In addition to the insertions/deletions of nucleotides, the message can also be revised by changing the identity of RNA nucleotides. These changes are achieved through the enzymatic alteration of the chemical composition of nucleobases, resulting in a new nucleotide identity considered as a nucleotide substitution.

The first example described was a C to U substitution within the ORF of apolipoprotein B (apoB). Apolipoproteins are essential components for lipid transport and lipid metabolism. ApoB primarily exists in two isoforms: apoB100 and apoB48. In humans, apoB100 is synthesized in the liver as an essential component of very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL) and low-density lipoproteins (LDL). ApoB48 is expressed in the small intestine and is present in chylomicrons and their remnants. The determination of the mRNA sequence of intestinal apoB revealed the post-transcriptional substitution of a C with a U in the CAA codon, resulting in an UAA stop codon. The editing of the mRNA therefore leads to a truncated protein product, i.e., apoB48, with distinct functions compared with full-length apoB100. The responsible cytosine deaminase complex required for editing apoB mRNA is APOBEC-1 together with RNA-binding auxiliary protein APOBEC-1.

**FIGURE 1** | Schematic representation of mRNA editing and its effect on translation. Editing of pre-mRNA transcripts can generate start codons (green) and stop codons (red) by insertions of nucleotides or by base conversions. Base conversions potentially remove stop codons causing a prolonged open reading frame (purple). mRNA editing in the coding sequences can lead to non-synonymous codon substitutions (blue). In addition, editing within the coding sequences or in the 3’ UTR of the mRNA can induce alternative splicing (yellow) and altered mRNA stabilities (dashed frame), respectively. Insertions or deletions of nucleotides can cause a restoration or even a creation of an ORF (gray arrow). Edited mRNAs are subsequently subjected to translation and result in shortened/extended protein products (red and purple, respectively) or functionally altered proteins (blue) (E: exon; ORF: open reading frame).
complementation factor (ACF) and the RNA-Binding-Motif-Protein-47 (RBM47) (reviewed in Refs 34–36). Through the identification of the editing complex a conserved RNA motif, the mooring sequence, has been revealed, which recruits the cytosine deaminase to the editing target. The identification of the conserved mooring sequence led to the discovery of additional mRNAs, such as the oncogene neurofibromin 1 (NF1), that are edited in humans.35

Thus far, C-to-U editing has only been observed in eukaryotes, but not in bacteria and archaea. C-to-U editing is highly prominent in plants. With only few exceptions, the mitochondrial and plastid mRNAs of all land plants show editing.37

C-to-U editing is certainly not restricted to the coding sequences of mRNAs. Several editing sites have been detected, particularly in the 3′ UTRs of mRNAs, which therefore do not alter the amino acid sequence of the resulting product.38,39 Thus far, it is not clear how these editing sites influence gene expression. It is feasible that altered sequences modulate the efficiency of the translation process, alter RNA-protein binding affinities and consequently regulate mRNA translation.38 In addition, miRNA target sites could be affected as described for A-to-I editing.39,40

In addition to the C-to-U editing, substitutions of U with C were observed in land plants and mammals.29 For example, in the Wilms tumor gene (WT1), encoding a zinc finger transcription factor, the U-to-C conversion results in an exchange of a leucine with a proline in the final protein.41 Although these editing events have been identified in rats, mice and humans, their functional roles, the editing mechanism itself and the executing enzymes remain elusive.41–43

Recently, also G-to-A editing has been described for the WT1 mRNA44 and the mRNA of human tryptophan hydroxylase (TPH).45 Thus far, little is known about the role and impact of the edited sites on the enzymatic activity of the synthesized protein. With the rise of high-throughput sequencing technologies, more examples will likely be revealed. Whether these substitutions add to the list of mRNA modifications that alter gene expression or turn out to be sequencing artifacts should be carefully evaluated in future studies.46,47

**A-to-I Editing**

The conversion of adenosine to inosine (I) is the most prevalent form of RNA editing. More than 100,000,000 editing sites were computationally predicted within the human transcriptome.48 Chemically, the process involves a hydrolytic deamination at the C6 position, resulting in the conversion of A to the rare nucleotide I. The substitution of this amino group as a hydrogen donor with a carbonyl-oxygen as a hydrogen acceptor generates a similar Watson–Crick edge as G. Therefore, this type of editing is also occasionally referred to as A-to-G editing.49 Consequently, editing within double-stranded RNA results in an I-U mismatch, and the translation machinery recognizes I as a G instead of an A, potentially resulting in an amino acid substitution.

The enzymes responsible for the deamination reaction are adenosine deaminases acting on RNA (ADARs). These enzymes are highly conserved across metazoans,50 but the number of genes and isoforms varies between different species (reviewed in Ref 51). In mammals, two catalytically active ADARs have been described: ADAR152 and ADAR2.53 A third member of the ADAR-family has been identified, i.e., ADAR3, but the catalytic function of this enzyme has not been demonstrated.54 ADAR1 and ADAR2 are expressed in a wide range of tissues, whereas ADAR3 is exclusively expressed in the brain.55 All ADARs have an N-terminal double-stranded RNA-binding domain (dsRBD) and a C-terminal deaminase domain in common. Therefore, double-stranded RNA regions of mRNAs,56 small RNAs57 and viral RNAs58 are targets for A-to-I editing. In mammals, ADARs are essential for development,56,59 and altered A-to-I editing of various RNAs has been associated with a wide range of diseases, such as Alzheimer’s disease or amyotrophic lateral sclerosis.60,61

In the human transcriptome, more than 99% of the editing sites are reported to be positioned in Alu sequences, which are short interspersed nuclear elements (SINEs).48 Millions of these repeat sequences have been identified in the human genome, and these sequences are particularly concentrated in gene-rich regions.62 Two repeat sequences are frequently observed in close proximity to each other, forming long double-stranded regions representing ideal targets for the editing machinery. The role of Alu sequence editing is currently being investigated. Alu sequence editing has been associated with enhanced degradation through RNase III Tudor staphylococcal nuclease (Tudor SN) activity,63 altered RNA structures, mRNA splicing64 and RNA-protein binding affinities.65

Although infrequent, the editing of protein-coding sequences dramatically affects the protein product. The interpretation of I as G by the translation machinery can lead to non-synonymous substitutions that significantly alter the function or activity of the protein products. The AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor
GluR-B is the first RNA substrate identified. Editing causes the substitution of the CAG codon, encoding glutamine, to a CIG codon, which encodes arginine. This amino acid exchange dramatically affects the Ca\textsuperscript{2+} permeability of the AMPA receptor. About 99% of the primary transcripts undergo editing at this position and therefore the vast majority of GluR-B subunits contain Arg but not the genetically encoded Gln. Mutational studies have shown that mutant mice harboring Gln instead of Arg die within weeks after birth. Another RNA transcript that undergoes editing is the mRNA of the serotonin receptor 5-HT\textsubscript{2C}. A total of 5 positions are edited, and these alterations affect the activity of the receptor as a result of altered receptor:G-protein coupling.

Insertions/deletions generate ORFs through the creation of start and stop codons within existing ORFs and nucleotide substitutions through deamination alter the codon identity, thereby affecting the amino acid sequence. Not only can A-to-I conversions change the genetic code and thereby influence gene expression, A-to-I editing even regulates regulatory small RNAs, such as miRNA. Numerous effects of A-to-I editing on the functions of miRNAs have been reported. The editing alters pri-miRNA biogenesis, miRNA expression and miRNA selectivity (reviewed in Ref 70). In addition, the miRNA target undergoes RNA editing, thereby altering the miRNA target sequence and consequently modulating miRNA-mediated regulation.

The effect of RNA editing on gene expression and particularly translation has been well investigated. Insertions/deletions generate ORFs through the creation of start and stop codons within existing ORFs and nucleotide substitutions through deamination alter the codon identity, thereby affecting the amino acid sequence (Figure 1). Far less is known about internal mRNA modifications, such as m\textsuperscript{6}A, Ψ, m\textsuperscript{5}C and m\textsuperscript{6}Am, which are abundant in coding sequences and the UTRs of mRNAs. Upon first sight, some of these modifications are not likely to significantly alter the base pairing characteristics or the stability of the modified mRNA. Nevertheless, recent studies have reported many unexpected aspects that are influenced through mRNA modifications, revealing them as important factors that regulate gene expression. This methyltransferase activity is also found in Drosophila, which does not have an equivalent of mammalian A-to-I editing.

mRNA MODIFICATIONS REGULATE TRANSLATION

N\textsuperscript{6}-methyladenosine

In the 1970s, N\textsuperscript{6}-methyladenosine (m\textsuperscript{6}A) was among the first post-transcriptional modifications reported as abundant at high levels within mRNAs. The m\textsuperscript{6}A modification has been identified in the mRNAs of eukaryal organisms ranging from yeast and plants to mammals. Recently m\textsuperscript{6}A has also been described as a naturally occurring mRNA modification in bacteria. Within eukaryotes m\textsuperscript{6}A is the most abundant internal mRNA modification, accounting for 0.1–0.5% of all As (m\textsuperscript{6}A/A), which translates to approximately three m\textsuperscript{6}A residues per mRNA.

The precise location of m\textsuperscript{6}A within transcripts is debated, primarily because initial techniques could not map m\textsuperscript{6}A at single-base resolution. The established high-throughput sequencing approaches are based on m\textsuperscript{6}A-specific antibodies, as m\textsuperscript{6}A does not affect base pairing and is not prone to chemical modifications that would facilitate detection, enabling refined mapping and detailed quantifications. m\textsuperscript{6}A is enriched in regions in direct proximity to stop codons, in long exons and transcription start sites.

In yeast m\textsuperscript{6}A is induced during meiosis, indicating that the introduction of m\textsuperscript{6}A might not only be cell type-dependent but also dynamic during the cell cycle and development.

Another layer of complexity and dynamics is added by the finding that these methylation are reversible, making m\textsuperscript{6}A unique between other thus far described modifications. The dynamic methylations and demethylations of A are mediated through distinct sets of proteins that have been rather well characterized. These enzymes can be divided into (1) m\textsuperscript{6}A ‘writers’, which deposit m\textsuperscript{6}A modifications, (2) m\textsuperscript{6}A ‘erasers’ that catalyze the removal of m\textsuperscript{6}A from the transcripts, and (3) m\textsuperscript{6}A ‘readers’, which mediate the downstream effects of this distinct mRNA modification (Figure 2). The first ‘writer’ described is METTL3 (methyltransferase-like 3), a 70 kDa protein, functioning as a methyltransferase within a multi-enzyme complex. Subsequently, METTL4 and METTL14 were bioinformatically identified, of which METTL14 has
been biochemically validated to directly interact with METTL3, forming a large 1 MDa heterodimeric methyltransferase enzyme complex (Figure 2).96,103 However, METTL3 and METTL14 both independently deposit m6A on transcripts, but show enhanced methylation activities in vitro and in vivo when combined.96,104 The m6A writer complex is joined by WTAP (Wilms’ tumor 1-associating protein), which itself does not exhibit methyltransferase activity, but might be crucial for the localization of the complex.96,97

The first ‘eraser’ identified is the demethylase FTO (fat mass and obesity-associated protein), which catalyzes the reversion of m6A to adenosine (Figure 2).83 The reaction proceeds via two labile intermediates, N6-hydroxymethyladenosine (hm6A) and N6-formyladenosine (f6A), whose biological functions remain elusive.94 A second m6A demethylase was identified in mammals, namely ALKBH5. This enzyme does not form intermediates and directly converts m6A to A.81,84

Whereas m6A writers and erasers have attracted interest in the past, because of the compelling dynamic nature of the m6A landscape and the unexpected link to human obesity,81,105,106 the characterization of m6A readers is of equal importance. These factors represent the direct link between m6A and its functional repertoire (Figure 2). YTH domain family members (YTHDF1-3 and YTHDC1) have been characterized as the first proteins to directly interact with m6A-modified mRNAs.4,86,107 The biological roles of these proteins remain largely elusive, as only YTHDF2 has been reported to target m6A-modified transcripts to mRNA decay sites in mammalian cells.4 YTHDF2 directly recognizes m6A-modified mRNAs via its carboxy-terminus and in turn controls the half-life of the respective mRNA. Interestingly, during yeast meiosis m6A might stimulate the translation, rather than mark the degradation, of the respective mRNAs.108

In addition, proteins that indirectly read m6A have been characterized.81 HNRNPC (heterogeneous nuclear ribonucleoprotein C) affects alternative splicing, and the binding of this protein to RNA is stimulated by altered local RNA structures caused through the methylation of adenosine. By influencing the structure of RNA, m6A indirectly attracts binding proteins.4,100 Additional connections between m6A and alternative splicing have also been proposed.101

Overall, the impact of m6A on RNA is extremely diverse, as this modification has been implicated as a circadian clock pacemaker that facilitates nuclear processing and mRNA export.102 Other groups have demonstrated an interplay between m6A and ncRNAs, i.e., m6A modifications promote primary-microRNA (pri-miRNA) processing, and vice versa miRNAs themselves can regulate m6A formation.
However, m\(^6\)A research is still facing a knowledge gap on how modified mRNAs are translated into proteins. Is the ribosome directly affected by m\(^6\)A modifications? If so, which step of translation is targeted? Zhou and colleagues have shown that m\(^6\)A promotes the initiation of translation via the m\(^6\)A reader protein YTHDF2.\(^98\) In response to heat stress m\(^6\)A methylations within the 5’ UTR of mRNAs are shielded from FTO-mediated demethylation by the binding of YTHDF2 and facilitate cap-independent translational initiation. In addition, a single m\(^6\)A residue within the 5’ UTR enabled the translation of an uncapped mRNA,\(^98\) potentially through the specific binding of the initiation factor eIF3.\(^113\)

Translation initiation is also regulated through YTHDF1.\(^99\) YTHDF1 selectively reads m\(^6\)A sites located near the 3’ end of mRNAs and promotes the translation of the respective mRNA via an interaction with the ribosomal initiation complex.\(^99\) Whereas the m\(^6\)A reader proteins YTHDF1 and YTHDF2 both promote translation by facilitating the rate-limiting step of translational initiation, YTHDF2 also determines the lifetime of an mRNA by chaperoning it to mRNA decay sites.\(^4,98,99,112\)

The role of m\(^6\)A and its interaction with diverse proteins has been extensively studied, but equally interesting are the interactions of modified bases with other nucleotides. m\(^6\)A exclusively base pairs with uridine, indicating that the N\(^6\)-methyl group does not alter canonical base pairing.\(^113\) Reverse transcriptase reverts both adenosine and m\(^6\)A to thymine. However, how does the ribosome process an m\(^6\)A-modified codon?

Initial studies employing methylated mRNAs have reported the stimulation of translation in a rabbit reticulocyte in vitro translation system.\(^114\) However, an increased m\(^6\)A content in mRNAs beyond 5% strongly inhibits translation.\(^3\) In these reports, neither the amount, nor the positions of the methylation sites were defined. Recent publications applied a systematic approach to analyze the impact of m\(^6\)A on translational elongation in bacterial systems.\(^115–117\) m\(^6\)A was site-specifically incorporated into the first, second, or third codon position of mRNAs employed for in vitro translation systems. Analyzing the protein products revealed codon position-dependent effects of m\(^6\)A.\(^116\) Methylated lysine codons (codon triplet: AAA) reduced translation rates, predominantly those with the N\(^\circ\)-methyl group present in the first codon position (m\(^6\)AAA). The second (Am\(^6\)AA) and the third codon position (AAm\(^6\)A) were less sensitive to this modification.\(^115,116\) A recent approach investigating the effects of m\(^6\)A on single steps of translational elongation led to the same conclusions and showed that m\(^6\)A delays tRNA accommodation.\(^113\) These reports suggest that m\(^6\)A sites might slow ribosomal decoding. Consequently, methylations could reduce protein yield or they might bring protein synthesis into accordance with protein folding or recognition by chaperones.\(^115,116\)

### Pseudouridine

In the early 1950s, prior to the characterization of m\(^6\)A, pseudouridine (Ψ) was isolated from calf liver and initially described as the ‘fifth nucleotide’.\(^118–121\) Pseudouridine, i.e., the C\(^5\)-glycoside isomer of the nucleoside uridine, is formed after the breakage of the N\(^1\)-glycosidic bond and a 180° rotation of the base through the attachment of the C\(^\circ\)\(^7\) atom to the sugar ring. The isomerization does not affect base pairing at the Watson–Crick edge, however, a second hydrogen bond donor is liberated at the Hoogsteen edge that equips Ψ with distinct chemical properties.\(^122\)

Generally, Ψ formation is catalyzed by two independent enzymatic reactions (Figure 3(a)). One mechanism to introduce Ψ depends on a subclass of small nucleolar RNAs (snoRNAs), i.e., H/ACA box snoRNAs.\(^122\) SnoRNAs can be divided into C/D box snoRNAs and H/ACA box snoRNAs, which catalyze the 2’-O-methylation and pseudouridylation of cellular RNAs, respectively. These molecules represent a diverse class of nucleolar, intermediated-sized ncRNAs, found in eukaryotes and archaea.\(^123,126\) Functional snoRNAs form ribonucleoprotein complexes (RNPs, snoRNPs) and guide catalytically active proteins to the target site via basepairing to the cognate RNA target sequence. In case of H/ACA box snoRNPs, the catalytically active RNP component is the pseudouridine synthase Cbf5/ dyskerin.\(^127–129\) The canonical target of a majority of snoRNAs is ribosomal RNA (rRNA), but small nuclear RNAs (snRNAs) are also modified through a distinct population of snoRNAs designated as Cajal body-specific RNAs (scARNAs).\(^130,131\) Interestingly, mRNAs have also been identified as putative snoRNA targets.\(^132\)

In contrast to snoRNPs, the ubiquitous group of pseudouridine synthase (PUS) proteins can modify tRNAs, rRNAs and snRNAs independently of guide RNAs.\(^133–136\) Instead, PUS proteins themselves recognize structural and sequence motifs of their target RNAs and perform the pseudouridylation.\(^133,136\)

Ψ is particularly enriched in rRNAs and tRNAs, but is also detected in snRNAs.\(^7,13,122,137,138\) However, more than 60 years after its initial characterization, several independent groups have also

---

**WIREs RNA Translating the epitranscriptome**

Volume 8, January/February 2017 © 2016 The Authors. *WIREs RNA* published by Wiley Periodicals, Inc.
identified \( \Psi \) within the mRNAs of eukaryotes.\(^{17,19,20,122,139}\) The pseudouridylation of mRNAs has not been previously described because of a lack of effective high-resolution detection methods. In 2014, three groups conducted \( \Psi \)-selective deep sequencing approaches based on the chemical treatment of RNA with CMC (\( N \)-cyclohexyl-\( N \)\(^{0} \)-\( (2\)-morpholinoethyl)carbodiimide metho-p-toluenesulfonate) and subsequent reverse transcription. CMC specifically labels \( \Psi \)s thereby blocking the reverse transcriptase one nucleotide downstream of the \( \Psi \) site. These sequencing techniques were designated as Pseudo-seq, \( \Psi \)-seq and PSI-seq.\(^{17,19,20,140}\) Several hundred \( \Psi \) sites in human and/or yeast mRNAs have been revealed with a subset of sites differentially modified in response to stress stimuli. Genetic experiments revealed several Pus proteins and/or snoRNAs as responsible for \( \Psi \) formation within mRNAs.\(^{17,19,20}\) Subsequently, a refined \( \Psi \) profiling method was developed that employed the pre-enrichment of \( \Psi \)-modified RNAs.\(^{139}\) The authors reported thousands of \( \Psi \) sites within mammalian mRNAs with a \( \Psi /U \) ratio of 0.2–0.6%, consistent with the number of m\(^{6}\)As within mRNAs.\(^{24,83,84,139}\)

\( \Psi \) formation is dynamically induced in response to environmental cues. However, unlike m\(^{6}\)A formation, the introduction might not be reversible, as \( \Psi \) forms an inert C-C bond.\(^{141}\) Nevertheless, it has been suggested that \( \Psi \) plays a global regulatory role. Schwartz and colleagues hypothesized that \( \Psi \)s stabilize mRNAs or alternatively target the respective transcripts to stress granules during heat stress.\(^{20,142}\) Alternatively, Carlile and colleagues suggested \( \Psi \)-induced structural changes to indirectly alter mRNA metabolism.\(^{17}\)
Karijolich and colleagues investigated the impact of Ψs on translation termination (Figure 3(b)). A pre-mature termination codon (PTC) in a reporter mRNA was site-specifically pseudouridylated employing artificial H/ACA box snoRNAs. The modified stop codon reduced recognition by release factors. Instead of releasing the peptide, a specific aminoacylated tRNA binds to the ribosomal A-site resulting in a read-through of the PTC. ΨAA and ΨAG stop codons resulted in serine and threonine incorporation, whereas ΨGA stop codons encoded tyrosine or phenylalanine. Ψs were not identified to be present in stop codons in vivo, and these findings therefore might not be relevant for regulating endogenous translation. However, Ψ-dependent stop codon readthrough could be applicable for the development of novel therapeutic approaches targeting pathological PTCs.

It is a longstanding enigma whether Ψ might also interfere with codon recognition during translation elongation. Thus, Ψs could potentially expand the genetic code through recoding translation, i.e., changes in the amino acid composition of the translated peptide, without adjustments in the primary nucleotide sequence of the mRNA. This debate was initially stimulated by a report demonstrating that pseudouridylated tRNA anticodons change codon preferences. Molecular dynamics simulations of Ψ in mRNAs supported the hypothesis of a possible recoding potential through Ψ. At least in a bacterial in vitro translation system, the incorporation of a single Ψ at all three possible positions of the phenylalanine codon (UUU) did not stimulate translational mis-recoding based on mass spectrometry of the synthesized peptides.

Whereas the decoding process is not affected by Ψs, the translational rates and protein expression levels increased. Moreover, HPLC-purified pseudouridylated mRNAs do not trigger an immune response and are more stable compared with mRNAs containing only uridine. Karikó and colleagues exploited these Ψ characteristics and injected Ψ-modified erythropoietin mRNAs into mice. Subsequently, these authors observed 10–100-fold increased erythropoietin levels compared with translation from U-containing mRNAs.

Although translation is a highly conserved process, the stimulating effect of Ψ on translation is not universal (Figure 3(c)). The random incorporation of several Ψs in transcripts enhanced translation in mice and in one mammalian in vitro translation system, i.e., rabbit reticulocyte lysate. In contrast, in wheat germ translation systems an inhibitory effect was observed. Several Ψs within an mRNA completely abolished translation in an E. coli based in vitro translation system, whereas single Ψs did not dramatically change E. coli translational rates and kinetics.

The mechanisms by which ribosomes interpret Ψs are diverse and are not conserved between the domains of life. Nevertheless, pseudouridylations might be attractive for clinical approaches, reflecting the particular characteristics of these modifications, e.g., for the efficient reprogramming of somatic cells to pluripotency employing Ψ-modified mRNAs.

After deciphering the Ψ-transcriptome and numerous sophisticated biochemical studies, Ψ remains an enigmatic mRNA modification, even 65 years after its initial detection.

5-Methylcytosine

5-Methylcytosine (m5C) is not only a well-characterized DNA modification e.g., reported to be an epigenetic marker in gene regulation and crucial for X-inactivation, but m5C also decorates RNA. Compared with m6A and Ψ, little is known about the functions of m5C within RNAs. Thus far, m5C has been identified in bacterial, archaeal and eukaryal rRNAs, whereas in the latter two domains, tRNAs are also m5C-modified. m5C has also been reported in ncRNAs and described to regulate their processing.

Viral and archael mRNAs are subjected to m5C modifications. Whether eukaryal mRNAs harbor m5C or not was a longstanding controversial question in the field. The results of previous studies conducted in the 1970s have been inconclusive, as m5C mRNA was detected in Hepa cells and at low levels in the hamster BHK-21 cells, but not in other rodent cell lines, i.e., Novikoff hepatoma and mouse myeloma cells.

With the rise of bisulfite deep sequencing and its adaptation for RNA research, m5C has gained much attention. In 2012, a global transcriptome analysis unveiled more than 10,000 m5C modification sites within human mRNAs. The mapped m5C pattern is not random, but rather is enriched in the UTRs of mRNAs and in the vicinity of Argonaute binding sites. Squires and colleagues implicated m5C in translational regulation, in analogy to m6A. Similar to m6A, the deposition of m5C appears to be dynamic. However, unlike m6A, the methylation has not yet been reported to be fully removed, but is oxidized to 5-hydroxymethylcytidine.
mRNAs harboring m$^5$Cs are translated in vitro at reduced levels, whereas hm$^4$C did not affect protein yields. In vivo, however, hm$^4$C containing mRNAs were associated with polysomes, indicating higher levels of translation. These results suggest a dynamic, regulatory role of cytosine base modifications. In contrast, earlier studies did not observe an inhibition, but a stimulating effect of m$^5$C on translation in vitro and in vivo. Therefore the influence of m$^5$C within coding sequences of mRNAs on eukaryal translation is not yet fully clarified.

The m$^5$C modification has not yet been identified within bacterial mRNA. However, employing a bacterial in vitro translation system, it was recently demonstrated that single m$^5$C modifications do not strongly inhibit protein synthesis independent of their localization within a codon. Instead, m$^5$C induces mis-recoding when positioned in the second codon position of a proline codon (Cm$^5$CC). Although the absolute number of mutated peptides was relatively low, the misincorporation of Cm$^5$CC codons was induced 50- to 500-fold, assuming an endogenous translational error rate of $10^{-3}$ to $10^{-4}$. Whether this mechanism is biologically relevant to increase protein diversity, such as deamination through RNA editing, needs to be addressed in future studies.

The Epitranscriptome Is Expanding

In the last decade of RNA research, significant technical advances have been made. With the refinement of next-generation sequencing and the rise of RNA mass spectrometry, RNA modifications have re-gained much attention. Thus, the RNA modification repertoire is constantly expanding and the significance of the RNA modifications involved in several cellular aspects is currently undisputed.

Methyllations of the ribose 2'-OH of mRNA nucleotides within the coding sequence have not unambiguously been identified thus far. However, there are indications that mRNAs are potentially methylated in a snoRNA-dependent manner. The class of C/D box snoRNAs typically guides a protein complex to the rRNA target, consequently leading to a 2'-O-methylation. However, so-called orphan snoRNAs have been identified and predicted to target other RNA species, such as mRNAs. snoRNA SNORD-115 has been suggested to methylate the pre-mRNA of 5-HT$_2C$, thereby potentially regulating gene expression. In vitro studies have shown that 2'-O-methylations, particularly at the second nucleotide of the codon strongly repress protein synthesis, independent of the sequence context. This finding suggests that 2'-O-methylation is a potent regulator of gene expression at the translation level.

Recently, two independent groups reported N$^1$-methyladenosine (m$^1$A) within thousands of the mRNAs of several human and murine cell lines and in yeast. Interestingly, the m$^1$A pattern is conserved in these cell types. Moreover, m$^1$A is dynamically deposited in response to environmental cues within 5' UTRs around canonical and alternative translation initiation sites and in highly structured RNA regions in the vicinity of start codons. m$^1$A also affects the structure of RNAs, together with the finding that m$^1$A-modified mRNAs are translated at higher rates compared with non-methylated mRNAs, the authors hypothesized that m$^1$A might affect mRNA folding around the translational initiation sites thereby facilitating translation. Alternatively, these authors reasoned that m$^1$A generates a binding site for proteins, thereby promoting initiation. Overall, the stress-induced deposition of m$^1$A, respectively its reversibility and the proposed implication in translation are reminiscent of m$^6$A.

A subset of mRNA modifications (m$^1$A, but also m$^5$A and Ψ) has been shown to be dynamically regulated and introduced within transcripts in response to stress. Nevertheless, RNA can also be damaged or ‘diversified’ upon excessive stress conditions. The insults, such as radiation, oxidation or damage through chemical agents, can be manifold, harming the RNA integrity. 8-oxoguanosine (8-oxoG), which emerges in oxidized RNAs, and O$^6$-methylguanosine (m$^6$G), known as DNA lesion have been recently investigated for their impact on protein synthesis. Nevertheless, RNA can also be damaged or ‘diversified’ upon excessive stress conditions. The insults, such as radiation, oxidation or damage through chemical agents, can be manifold, harming the RNA integrity. 8-oxoguanosine (8-oxoG), which emerges in oxidized RNAs, and O$^6$-methylguanosine (m$^6$G), known as DNA lesion have been recently investigated for their impact on protein synthesis. 8-oxoG hinders tRNA selection and reduces peptide-bond formation rates, thereby inducing ribosome stalling. Similarly, m$^6$G also affects translation only when present in the second codon position. These reports indicate that modified nucleotides, as a result of mRNA damage, can severely affect a cell, and that the ribosome is a major target not only of regulatory but also of aberrant mRNA modifications.

CONCLUSION

The emerging roles of mRNA modifications are extremely diverse, ranging from inducing mRNA decay to RNA structural alterations or varying protein binding affinities. RNA modifications have been unveiled in unexpected places in mRNAs, thereby additionally expanding the potential functional repertoire (summarized in Table 1). It will be an exciting
and challenging future task to distinguish between meaningful epitranscriptomal marks and silent bystander modifications that simply decorate nucleic acids. Thus, it is crucial to validate data originating from large-scale sequencing studies through technically independent assays to eradicate sequencing artifacts. A promising technique to depict the modification status of a specific transcript’s site has previously been successfully applied to m^6^A- andΨ-modified RNAs, respectively, but might also be applicable to other RNA modifications.130,178

It will also be challenging to refine the reported modification patterns to single nucleotide resolution. Sequencing approaches based on immuno-precipitation narrow down the modification site, but do not precisely map the modified nucleotides. However, improvements of these high-throughput approaches enable the identification of some mRNA modifications at single nucleotide resolution.85,157,161 Consequently, this will allow refining the modification patterns and will enable the identification of reliable consensus sequences for the entire set of modifying enzymes.

mRNA modifications also modulate protein synthesis (Table 1). Initial studies have indicated that this effect is dependent on the codon position of the modification and in the mRNA sequence context. It will be crucial to define which modified codons directly affect the ribosome as potential regulators of translation. In addition, the mechanism behind this regulatory function will certainly reveal some exciting new insights in the decoding process of modified mRNA nucleotides. Because of the high degree of conservation, it would be expected that all translation systems manage mRNA modifications in similar manner. Nevertheless, contrasting results were obtained, raising a key question: Why is the interpretation of modified codons by the ribosome not universally conserved across different species? It might even be conceivable that within one species, the translational response might vary in different tissues.

RNA modifications were initially described decades ago, whereas the knowledge concerning the presence of these modifications within the coding sequence of mRNAs is rather novel. Thus, investigating the influence of these modifications on pivotal cellular processes, such as mRNA translation, will generate new research opportunities and will change our understanding of gene regulation.

**ACKNOWLEDGMENTS**

We would like to thank Nina Clementi, Roman Kessler, Alexander Hüttenhofer and Norbert Polacek for critically reading the manuscript and helpful discussions. This work was funded by the Austrian Science Fund (FWF) (P 22658-B12 and P 28494-B11 to M.E).
REFERENCES

1. Warner JR. The economics of ribosome biosynthesis in yeast. Trends Biochem Sci 1999, 24:437–440.

2. Lafontaine DL. Noncoding RNAs in eukaryotic ribosome biogenesis and function. Nat Struct Mol Biol 2015, 22:11–19.

3. Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouracil into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008, 16:1833–1840.

4. Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 2014, 505:117–120.

5. Helm M. Post-transcriptional nucleotide modification and alternative folding of RNA. Nucleic Acids Res 2006, 34:721–733.

6. El Yacoubi B, Bailly M, de Crécy-Lagard V. Biosynthesis and function of posttranscriptional modifications of transfer RNAs. Annu Rev Genet 2012, 46:69–95.

7. Phizicky EM, Hopper AK. tRNA biology charges to the front. Genes Dev 2010, 24:1832–1860.

8. Machnicka MA, Milanowska K, Osman Oglou O, Purta E, Kurkowska M, Olchowik A, Januszewski W, Kalinowski S, Dunin-Horkawicz S, Rother KM, et al. MODOMICS: a database of RNA modification pathways–2013 update. Nucleic Acids Res 2013, 41: D262–D267.

9. Madore E, Florentz C, Giegé R, Sekine S, Yokoyama S, Lapointe J. Effect of modified nucleotides on Escherichia coli tRNA G-U structure and on its aminoacylation by glutamyl-tRNA synthetase. Prepr Biol 2015, 22:342–344.

10. Maden BE. The numerous modified nucleotides in eukaryotic ribosomal RNA. Prog Nucleic Acid Res Mol Biol 1990, 39:241–303.

11. Maden BE. The numerous modified nucleotides in Escherichia coli? Biochimie 2015, 117:110–118.

12. Phizicky EM, Alfonzo JD. Do all modifications benefit all tRNAs? FEBS Lett 2010, 584:265–271.

13. Maden BE. The numerous modified nucleotides in eukaryotic ribosomal RNA. Prog Nucleic Acid Res Mol Biol 1990, 39:241–303.

14. Sergeeva OV, Bogdanov AA, Sergiev PV. What do we know about ribosomal RNA methylation in Escherichia coli? Biochimie 2015, 117:110–118.

15. Erlacher MD, Chirkova A, Voegele P, Polacek N. Generation of chemically engineered ribosomes for atomic mutagenesis studies on protein biosynthesis. Nat Protoc 2011, 6:580–592.

16. Liiv A, Karitkina D, Maiivai U, Remme J. Analysis of the function of E. coli 23S rRNA helix-loop 69 by mutagenesis. BMC Mol Biol 2005, 6:18.

17. Carlile TM, Rojas-Duran MF, Zinshteyn B, Shin H, Bartoli KM, Gilbert WV. Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells. Nature 2014, 515:143–146.

18. Edelheit S, Schwartz S, Mumbach MR, Wurtzel O, Sorek R. Transcriptome-wide mapping of 5-methylcytidine RNA modifications in bacteria, archaea, and yeast reveals m5C within archaeal mRNAs. PLoS Genet 2013, 9:e1003602.

19. Lovejoy AF, Riordan DP, Brown PO. Transcriptome-wide mapping of pseudouridines: pseudouridine synthases modify specific mRNAs in S. cerevisiae. PLoS One 2014, 9:e110799.

20. Schwartz S, Bernstein DA, Mumbach MR, Jovanovic M, Herbst RH, León-Ricardo BX, Engreitz JM, Guttman M, Satija R, Lander ES, et al. Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. Cell 2014, 159:148–162.

21. Li X, Xiong X, Wang L, Shu X, Ma S, Y C. Transcriptome-wide mapping reveals reversible and dynamic N(1)-methyladenosine methylome. Nat Chem Biol 2016, 12:311–316.

22. Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, Peer E, Kol N, Ben-Haim MS, Dai Q, Di Segni A, Salmon-Divon M, Clark WC, et al. The dynamic N(1)-methyladenosine methylome in eukaryotic messenger RNA. Nature 2016, 530:441–446.

23. Schaub M, Keller W. RNA editing by adenosine deaminases generates RNA and protein diversity. Biochimie 2002, 84:791–803.

24. Dubin DT, Taylor RH. The methylation state of poly A-containing messenger RNA from cultured hamster cells. Nucleic Acids Res 1975, 2:1653–1668.

25. Deng X, Chen K, Luo GZ, Weng X, Ji Q, Zhou T, He C. Widespread occurrence of N6-methyladenosine in bacterial mRNA. Nucleic Acids Res 2015, 43:6537–6567.

26. Benne R, Van den Burg J, Brakenhoff JP, Sloop P, Van Boom JH, Tromp MC. Major transcript of the 5.8S rRNA. J Biochem 1990, 39:241–244.

27. Goetz JM, Emeson RB. Functions and mechanisms of RNA editing. Annu Rev Genet 2000, 34:499–531.
28. Feagin JE, Abraham JM, Stuart K. Extensive editing of the cytochrome c oxidase III transcript in Trypanosoma brucei. Cell 1988, 53:413–422.

29. Smith HC. Editing informational content of expressed DNA sequences and their transcripts. In: Caporale LH, ed. The Implicit Genome. New York: Oxford University Press Inc; 2006, 248–265.

30. Byrne EM, Gott JM. Cotranscriptional editing of Physarum mitochondrial RNA requires local features of the native template. RNA 2002, 8:1174–1183.

31. Chen SH, Habib G, Yang CY, Gu ZW, Lee BR, Weng SA, Silberman SR, Cai SJ, Deslypere JP, Rosseneu M, et al. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science 1987, 238:363–366.

32. Powell LM, Wallis SC, Pease RJ, Edwards YH, Knott TJ, Scott J. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell 1987, 50:831–840.

33. Olofsson SO, Borén J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherosclerotic lipoproteins and promotes the development of atherosclerosis. J Intern Med 2005, 258:395–410.

34. Smith HC, Bennett RP, Salter JD, Smith HC. The multifaceted roles of RNA binding in APOBEC cytidine deaminase functions. WIREs RNA 2014, 5:493–508.

35. Fossat N, Tourle K, Radziewicz T, Barratt K, Liebhold D, Studdert JB, Power M, Jones V, Loebel DA, Tam PP. To C to U RNA editing mediated by APOBEC1 requires RNA-binding protein RBM47. EMBO Rep 2014, 15:903–910.

36. Takenaka M, Zehrmann A, Verbitskiy D, Hartel B, Brennicke A. RNA editing in plants and its evolution. Annu Rev Genet 2013, 47:335–352.

37. Blanc V, Park E, Schaefer S, Miller M, Lin Y, Kennedy S, Billing AM, Ben Hamidane H, Graumann J, Mortazavi A, et al. Genome-wide identification and functional analysis of Apobec-1-mediated C-to-U RNA editing in mouse small intestine and liver. Genome Biol 2014, 15:R79.

38. Rosenberg BR, Hamilton CE, Mwangi MM, Dewell S, Papavasiliou FN. Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3' UTRs. Nat Struct Mol Biol 2011, 18:230–236.

39. Hundleby HA, Bass BL. ADAR editing in double-stranded UTRs and other noncoding RNA sequences. Trends Biochem Sci 2010, 35:377–383.

40. Sharma PM, Bowman M, Madden SL, Rauscher FJ 3rd, Sukumar S. RNA editing in the Wilms' tumor susceptibility gene, WT1. Genes Dev 1994, 8:720–731.

41. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 2006, 15 Spec No 2:R196–R201.

42. Wagner KD, Wagner N, Schell A. The complex life of WT1. J Cell Sci 2003, 116:1653–1658.

43. Niavarani A, Currie E, Yal Y, Anjos-Afonso F, Horswell S, Griessinger E, Luis Sardina J, Bonnet D. APOBEC3A is implicated in a novel class of G-to-A mRNA editing in WT1 transcripts. PLoS One 2015, 10:e0120089.

44. Grohmann M, Hammer P, Walther M, Paulmann N, Böttner A, Eisenmenger W, Baghai TC, Schüle C, Rupprecht R, Bader M, et al. Alternative splicing and extensive RNA editing of human TPH2 transcripts. PLoS One 2010, 5:e8956.

45. Kim MS, Hur B, Kim S. RDDpred: a condition-specific RNA-editing prediction model from RNA-seq data. BMC Genomics 2016, 17(Suppl 1):5.

46. Bass B, Hundleby H, Li JB, Peng Z, Pickrell J, Xiao XG, Yang L. The difficult calls in RNA editing. Interviewed by H Craig Mak. Nat Biotechnol 2012, 30:1207–1209.

47. Bazak L, Haviv A, Barak M, Jacob-Hirsch J, Deng P, Zhang R, Isaacs FJ, Rechavi G, Li JB, Eisenberg E, et al. A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res 2014, 24:365–376.

48. Nishikura K. Editor meets silencer: crosstalk between RNA editing and RNA interference. Nat Rev Mol Cell Biol 2006, 7:919–931.

49. Jin Y, Zhang W, Li Q. Origins and evolution of ADAR-mediated RNA editing. IUBMB Life 2009, 61:572–578.

50. Savva YA, Rieder LE, Reenan RA. The ADAR protein family. Genome Biol 2012, 13:252.

51. Kim U, Wang Y, Sanford T, Zeng Y, Nishikura K. Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci USA 1994, 91:11457–11461.

52. Melcher T, Maas S, Herb A, Sprengel R, Seeburg PH, Higuchi M. A mammalian RNA editing enzyme. Nature 1996, 379:460–464.

53. Chen CX, Cho DS, Wang Q, Lai F, Carter KC, Nishikura K. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA 2000, 6:755–767.

54. Deftit SN, Hundleby HA. To edit or not to edit: regulation of ADAR editing specificity and efficiency. WIREs RNA 2016, 7:113–127.

55. Higuchi M, Single FN, Kohler M, Sommer B, Sprengel R, Seeburg PH. RNA editing of AMPA
57. Tomaselli S, Bonamassa B, Alisi A, Nobili V, Locatelli F, Gallo A. ADAR enzyme and miRNA story: a nucleotide that can make the difference. Int J Mol Sci 2013, 14:22796–22816.
58. Samuel CE. Adenine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology 2011, 411:180–193.
59. Wang Q, Miyakoda M, Yang W, Khillan J, Stachura DL, Weiss MJ, Nishikura K. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem 2004, 279:4952–4961.
60. Zipeto MA, Jiang Q, Melese E, Jamieson CH. RNA rewriting, recoding, and rewiring in human disease. Trends Mol Med 2015, 21:549–559.
61. Avesson L, Barry G. The emerging role of RNA and glutamate-gated channels. Trends Biochem Sci 2014, 39:1845–1859.
62. Korenberg JR, Rykowski MC. Human genome organization: Alu, lines, and the molecular structure of metaphase chromosome bands. Cell 1988, 53:391–400.
63. Zhang Z, Carmichael GG. The fate of dsRNA in the nucleus: a p54{nr} containing complex mediates the nuclear retention of promiscuously A-to-I edited RNAs. Cell 2001, 106:465–475.
64. Lev-Maor G, Sorek R, Shamir N, Ast G. The birth and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science 1995, 270:1677–1680.
65. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 1997, 387:303–308.
66. Maas S, Rich A. Changing genetic information through RNA editing. Bioessays 2000, 22:790–802.
67. Wang Q, Hui H, Guo Z, Zhang W, Hu Y, He T, Tai Y, Peng P, Wang L. ADAR1 regulates ARHGAP26 gene expression through RNA editing by disrupting miR-30b-3p and miR-573 binding. RNA 2013, 19:1525–1536.
68. Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci USA 1974, 71:3971–3975.
69. Lavi S, Shatkin AJ. Methylated simian virus 40-specific RNA from nuclei and cytoplasm of infected BSC-1 cells. Proc Natl Acad Sci USA 1973, 72:2012–2016.
70. Perry RP, Kelley DE, LaTorre J. Synthesis and turnover of nuclear and cytoplasmic polyadenylic acid in mouse L cells. J Mol Biol 1974, 82:315–331.
71. Wei CM, Gershowitz A, Moss B. Methylated nucleotides block 5′ terminus of HeLa cell messenger RNA. Cell 1973, 4:379–386.
72. Adams JM, Cory S. Modified nucleosides and bizarre 5′ termini in mouse myeloma mRNA. Nature 1975, 255:28–33.
73. Clancy MJ, Shambaugh ME, Timpte CS, Bokar JA. Induction of sporulation in Saccharomyces cerevisiae leads to the formation of N6-methyladenosine in mRNA: a potential mechanism for the activity of the IME4 gene. Nucleic Acids Res 2002, 30:4509–4518.
74. Nichols JL, Welder L. A modified nucleotide in the poly(A) tract of maize RNA. Biochim Biophys Acta 1981, 652:99–108.
75. Pan T. N6-methyl-adenosine modification in messenger and long non-coding RNA. Trends Biochem Sci 2013, 38:204–209.
76. Wei CM, Gershowitz A, Moss B. 5′-Terminal and internal methylated nucleotide sequences in HeLa cell mRNA. Biochemistry 1976, 15:397–401.
77. Ya C, Liu J, He C. RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation. Genes Dev 2015, 29:1343–1355.
78. Dubin DT, Stollar V. Methylation of Sindbis virus ‘26S’ messenger RNA. Biochem Biophys Res Comm 1975, 66:1373–1379.
79. Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Yi C, Lu Y, Peng P, Wang L. ADAR1 regulates m6A and m6Am throughout the transcriptome. Nat Methods 2015, 12:767–772.
86. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K, Jacob-Hirsch J, Amariglio N, Kupiec M, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. *Nature* 2012, 485:201–206.

87. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. *Cell* 2012, 149:1635–1646.

88. Schwartz S, Mumbach MR, Jovanovic M, Wang T, Maciag K, Bushkin GG, Mertins P, Ter-Ovanesyan D, Habib N, Cacchiarelli D, et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites. *Cell Rep* 2014, 8:284–296.

89. Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible m(6)A RNA methylation. *Nat Rev Genet* 2014, 15:293–306.

90. Batista PJ, Molinie B, Wang J, Qu K, Zhang J, Li L, Bouley DM, Lujan E, Haddad B, Daneshvar K, et al. m(6)A RNA modification controls cell fate transition in mammalian embryonic stem cells. *Cell Stem Cell* 2014, 15:707–719.

91. Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol N, Salmon-Divon M, Hershkovitz V, Peer E, Mor N, Manor YS, et al. Stem cells. m6A mRNA methylation facilitates resolution of naive pluripotency toward differentiation. *Science* 2015, 347:1002–1006.

92. Schwartz S. Cracking the epitranscriptome. RNA 2016, 22:169–174.

93. Agarwala SD, Blitzblau HG, Hoch wagon A, Fink GR. RNA methylation by the MIS complex regulates a cell fate decision in yeast. *PLoS Genet* 2012, 8:e1002732.

94. Fu Y, Jia G, Pang X, Wang RN, Wang X, Li CJ, Smeno S, Dai Q, Bailey KA, Nobrega MA, et al. FTO-mediated formation of N6-hydroxymethyladenosine and N6-formyladenosine in mammalian RNA. *Nat Commun* 2013, 4:1798.

95. Bokar JA, Rath-Shambaugh ME, Ludwiczak R, Narayan P, Rottman F. Characterization and partial purification of mRNA N6-adenosine methyltransferase from HeLa cell nuclei. Internal mRNA methylation requires a multisubunit complex. *J Biol Chem* 1994, 269:17697–17704.

96. Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, Jia G, Yu M, Lu Z, Deng X, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. *Nat Chem Biol* 2014, 10:93–95.

97. Ping XL, Sun BF, Wang L, Xiao W, Yang X, Wang WJ, Adhikari S, Shi Y, Lv Y, Chen YS, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. *Cell Res* 2014, 24:177–189.

98. Zhou J, Wan J, Gao X, Zhang X, Jaffrey SR, Qian SB. Dynamic m(6)A mRNA methylation directs translational control of heat shock response. *Nature* 2015, 526:591–594.

99. Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, Weng X, Chen K, Shi H, He C. N(6)-methyladenosine modulates messenger RNA translation efficiency. *Cell* 2015, 161:1388–1399.

100. Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. *Nature* 2015, 518:560–564.

101. Zhao X, Yang Y, Sun BF, Shi Y, Yang X, Xiao W, Hao YJ, Ping XL, Chen YS, Wang WJ, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. *Cell Res* 2014, 24:1403–1419.

102. Fustin JM, Doi M, Yamaguchi Y, Hida H, Nishimura S, Yoshida M, Isagawa T, Morioka MS, Kakeya H, Manabe I, et al. RNA-methylation-dependent RNA processing controls the speed of the circadian clock. *Cell* 2013, 153:793–806.

103. Bujnicki JM, Feder M, Radlinska M, Blumenthal RM. Structure prediction and phylogenetic analysis of a functionally diverse family of proteins homologous to the MT-A70 subunit of the human mRNA:m(6)A methyltransferase. *J Mol Evol* 2002, 54:431–444.

104. Wang Y, Li Y, Toth JI, Petrokosi MD, Zhang Z, Zhao JC. N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells. *Nat Cell Biol* 2014, 16:191–198.

105. Dina C, Meyre D, Gallina S, Durand E, Körner A, Jacobsson P, Carlsson LM, Kiess W, Vatin V, Lecoeur C, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. *Nat Genet* 2007, 39:724–726.

106. Hess ME, Bruning JC. The fat mass and obesity-associated (FTO) gene: obesity and beyond? *Biochim Biophys Acta* 2014, 1842:2039–2047.

107. Xu C, Wang X, Liu K, Roundtree IA, Tempel W, Li Y, Lu Z, He C, Min J. Structural basis for selective binding of m6A RNA by the YTHDC1 YTH domain. *Nat Chem Biol* 2014, 10:927–929.

108. Bodi Z, Bottoni A, Archer N, May ST, Fray RG. Yeast m6A methylated mRNAs are enriched on translating ribosomes during meiosis, and under rapamycin treatment. *PLoS One* 2015, 10:e0132090.

109. Alarcón CR, Lee H, Goodarzi H, Halberg N, Tavazoie SF. N6-methyladenosines marks primary microRNAs for processing. *Nature* 2015, 519:482–485.
10. Chen T, Hao YJ, Zhang Y, Li MM, Wang M, Han W, Wu Y, Lv Y, Hao J, Wang L, et al. m(6)A RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency. Cell Stem Cell 2015, 16:289–301.

11. Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabkin MA, Elemento O, Pestova TV, Qian SB, Jaffrey SR. 5' UTR m(6)A promotes cap-independent translation. Cell 2015, 163:999–1010.

12. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009, 136:731–745.

13. Roost C, Lynch SR, Batista PJ, Qu K, Chang HY, Kool ET. Structure and thermodynamics of N6-methyladenosine in RNA: a spring-loaded base modification. J Am Chem Soc 2015, 137:2107–2115.

14. Heilman KL, Leach RA, Tuck MT. Internal 6-methyladenine residues increase the in vitro translation efficiency of dihydrofolate reductase messenger RNA. Int J Cell Biol 1996, 28:823–829.

15. Choi J, Ieong KW, Demirci H, Chen J, Petrov A, Prabhakar A, O’Leary SE, Dominissini D, Rechavi G, Solris SM, et al. N(6)-methyladenosine in mRNA disrupts tRNA selection and translationelongation dynamics. Nat Struct Mol Biol 2016, 23:110–115.

16. Hoernes TP, Clementi N, Faserl K, Glasner H, Breuker K, Lindner H, Hüttenthaler A, Erlacher MD. Nucleotide modifications within bacterial messenger RNAs regulate their translation and are able to rewrite the genetic code. Nucleic Acids Res 2016, 44:852–862.

17. Hoernes TP, Erlacher MD. Methylated mRNA nucleotides as regulators for ribosomal translation. Methods Mol Biol, in press.

18. Cohn WE. Some results of the applications of ionexchange chromatography to nucleic acid chemistry. J Cell Physiol Suppl 1951, 38:21–40.

19. Cohn WE. Pseudouridine, a carbon-carbon linked ribonucleoside in ribonucleic acids: isolation, structure, and chemical characteristics. J Biol Chem 1960, 235:1488–1498.

20. Scannell JP, Crestfield AM, Allen FW. Methylation studies on various uracil derivatives and on an isomer of uridine isolated from ribonucleic acids. Biochim Biophys Acta 1959, 32:406–412.

21. Yu CT, Allen FW. Studies on an isomer of uridine isolated from ribonucleic acids. Biochim Biophys Acta 1959, 32:393–406.

22. Ge J, Yu YT. RNA pseudouridylation: new insights into an old modification. Trends Biochem Sci 2013, 38:210–218.

23. Karrijolich J, Yu YT. Converting nonsense codons into sense codons by targeted pseudouridylation. Nature 2011, 474:395–398.

24. Fernández IS, Ng CL, Kelley AC, Wu G, Yu YT, Ramakrishnan V. Unusual base pairing during the decoding of a stop codon by the ribosome. Nature 2013, 500:107–110.

25. Williams GT, Farzaneh F. Are snoRNAs and snoRNA host genes new players in cancer? Nat Rev Cancer 2012, 12:84–88.

26. Hickey AJ, Macario AJ, Conway de Macario E. Identification of genes in the genome of the archaeon Methanosarcina mazei that code for homologs of nuclear eukaryotic molecules involved in RNA processing. Gene 2000, 253:77–85.

27. Bortolin ML, Ganot P, Kiss T. Elements essential for accumulation and function of small nucleolar RNAs directing site-specific pseudouridylation of ribosomal RNAs. EMBO J 1999, 18:457–469.

28. Lafontaine DL, Bousquet-Antonelli C, Henry Y, Caizergues-Ferrer M, Tollervey D. The box H + ACA snoRNAs carry Chp5p, the putative rRNA pseudouridine synthase. Genes Dev 1998, 12:527–537.

29. Zebarjad A, King T, Fourmier MJ, Clarke I, Carbon J. Point mutations in yeast CBFS can abolish in vivo pseudouridylation of rRNA. Mol Cell Biol 1999, 19:7461–7472.

30. Wu G, Yu AT, Kantartzis A, Yu YT. Functions and mechanisms of spliceosomal small nuclear RNA pseudouridylation. WIREs RNA 2011, 2:571–581.

31. Darzacq X, Jady BE, Verheggen C, Kiss AM, Bertrand E, Kiss T. Cajal body-specific small nuclear RNAs: a novel class of 2’-O-methylation and pseudouridylation guide RNAs. EMBO J 2002, 21:2746–2756.

32. Cavaillé J, Buiting K, Kiefmann M, Lalande M, Brannan CI, Horsthemke B, Bachellerie JP, Brosius J, Hüttenthaler A. Identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization. Proc Natl Acad Sci USA 2000, 97:14311–14316.

33. Arluison V, Hountondji C, Robert B, Grosjean H. Transfer RNA-pseudouridine synthetase Pus1 of Saccharomyces cerevisiae contains one atom of zinc essential for its native conformation and tRNA recognition. Biochemistry 1998, 37:7268–7276.

34. Chen J, Patton JR. Cloning and characterization of a mammalian pseudouridine synthase. RNA 1999, 5:409–419.

35. Motorin Y, Keith G, Simon C, Foiret D, Simos G, Hurt E, Grosjean H. The yeast tRNA:pseudouridine synthase Pus1p displays a multisite substrate specificity. RNA 1998, 4:856–869.

36. Urban A, Behm-Ansmant I, Branlant C, Motorin Y. RNA sequence and two-dimensional structure features required for efficient substrate modification by the Saccharomyces cerevisiae RNA[(Psi)]-synthase Pus7p. J Biol Chem 2009, 284:5845–5858.
137. Branlant C, Krol A, Machatt MA, Pouyet J, Ebel JP, Edwards K, Kössel H. Primary and secondary structures of Escherichia coli MRE 600 23S ribosomal RNA. Comparison with models of secondary structure for maize chloroplast 23S rRNA and for large portions of mouse and human 16S mitochondrial RNAs. *Nucleic Acids Res* 1981, 9:4303–4324.

138. Yu AT, Ge J, Yu YT. Pseudouridines in spliceosomal snRNAs. *Protein Cell* 2011, 2:712–725.

139. Li X, Zhu P, Ma S, Song J, Bai J, Sun F, Yi C. Chemical pulldown reveals dynamic pseudouridylation of the mammalian transcriptome. *Nat Chem Biol* 2015, 11:592–597.

140. Bakin A, Ofengand J. Four newly located pseudouridylate residues in Escherichia coli 23S ribosomal RNA are all at the peptidyltransferase center: analysis by the application of a new sequencing technique. *Biochemistry* 1993, 32:9754–9762.

141. Zhao BS, He C. Pseudouridine in a new era of RNA modifications. *Cell Res* 2015, 25:153–154.

142. Kierzek E, Malgowska M, Lisowiec J, Turner DH, Gdaniec Z, Kierzek R. The contribution of pseudouridine to stabilities and structure of RNAs. *Nucleic Acids Res* 2014, 42:3492–3501.

143. Karijolich J, Yu YT. Therapeutic suppression of premature termination codons: mechanisms and clinical considerations (review). *Int J Mol Med* 2014, 34:355–362.

144. Parisien M, Yi C, Pan T. Rationalization and prediction of selective decoding of pseudouridine-modified nonsense and sense codons. *RNA* 2012, 18:355–367.

145. Tomita K, Ueda T, Watanabe K. The presence of pseudouridine in the anticodon alters the genetic code: a possible mechanism for assignment of the AAA lysine codon as asparagine in echinoderm mitochondria. *Nucleic Acids Res* 1999, 27:1683–1689.

146. Anderson BR, Muramatsu H, Nallagatla SR, Bevilacqua PC, Sansing LH, Weissman D, Karikó K. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. *Nucleic Acids Res* 2010, 38:5884–5892.

147. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity* 2005, 23:165–175.

148. Karikó K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. *Nucleic Acids Res* 2011, 39:e142.

149. Karikó K, Muramatsu H, Keller JM, Weissman D. Increased erythropoiesis in mice injected with submicromolar quantities of pseudouridine-containing mRNA encoding erythropoietin. *Mol Ther* 2012, 20:948–953.

150. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. *Cell Stem Cell* 2010, 7:618–630.

151. Basu R, Zhang LF. X chromosome inactivation: a silence that needs to be broken. *Genesis* 2011, 49:821–834.

152. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. *Annu Rev Pharmacol Toxicol* 2009, 49:243–263.

153. Hayashi Y, Osawa S, Miura K. The methyl groups in ribosomal RNA from *Escherichia coli*. *Biochim Biophys Acta* 1966, 129:519–531.

154. Klagsbrun M. An evolutionary study of the methylation of transfer and ribosomal nucleic acid in prokaryote and eukaryote organisms. *J Biol Chem* 1973, 248:2612–2620.

155. Noon KR, Bruenger E, McCloskey JA. Posttranscriptional modifications in 16S and 23S rRNAs of the archaeal hyperthermophile *Sulfolobus solfataricus*. *J Bacteriol* 1998, 180:2883–2888.

156. Hussain S, Sajini AA, Blanco S, Dietmann S, Lombard P, Sugimoto Y, Paramor M, Gleson JG, Odom DT, Ule J, et al. NSun2-mediated cytosine-5 methylation of vault noncoding RNA determines its processing into regulatory small RNAs. *Cell Rep* 2013, 4:255–261.

157. Amort T, Soulière MF, Wille A, Jia XY, Fiegl H, Wörle H, Micura R, Lusser A. Long non-coding RNAs as targets for cytosine methylation. *RNA Biol* 2013, 10:1003–1008.

158. Sommer S, Saludd-Georgieff M, Bachenheimer S, Darnell JE, Furuiuchi Y, Morgan M, Shafkin AJ. The methylation of adenovirus-specific nuclear and cytoplasmic RNA. *Nucleic Acids Res* 1976, 3:749–765.

159. Saludd-Georgieff M, Jelinek W, Darnell JE, Furuiuchi Y, Morgan M, Shafkin A. Methyl labeling of HeLa cell hnRNA: a comparison with mRNA. *Cell* 1976, 7:227–237.

160. Schaefer M, Pollex T, Hanna K, Lyko F. RNA cytosine methylation analysis by bisulfite sequencing. *Nucleic Acids Res* 2009, 37:e12.

161. Squires JE, Patel HR, Nousch M, Sibbritt T, Humphreys DT, Parker BJ, Suter CM, Preiss T. Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA. *Nucleic Acids Res* 2012, 40:5023–5033.

162. Fu L, Guerrero CR, Zhong N, Amato NJ, Liu Y, Liu S, Cai Q, Ji D, Jin SG, Niedernhofer LJ, et al. Tet-mediated formation of 5-hydroxymethylcytosine in RNA. *J Am Chem Soc* 2014, 136:11582–11585.
163. Huber SM, van Delft P, Mendil L, Bachman M, Smollett K, Werner F, Miska EA, Balasubramanian S. Formation and abundance of 5-hydroxymethylcytosine in RNA. *ChemBioChem* 2015, 16:752–755.

164. Delatte B, Wang F, Ngoc LV, Collignon E, Bonvin E, Deplus R, Calonne E, Hassabi B, Putmans P, Awe S, et al. Transcriptome-wide distribution and function of RNA hydroxymethylcytosine. *Science* 2016, 351:282–285.

165. Edelmann P, Gallant J. Mistranslation in *E. coli*. Cell 1977, 10:131–137.

166. Kramer EB, Farabaugh PJ. The frequency of translational misreading errors in *E. coli* is largely determined by tRNA competition. *RNA* 2007, 13:87–96.

167. Wetzel C, Limbach PA. Mass spectrometry of modified RNAs: recent developments. *Analyst* 2016, 141:16–23.

168. Bachellerie JP, Cavaillé J, Hüttenhofer A. The expanding snRNA world. *Biochimie* 2002, 84:775–790.

169. Hüttenhofer A, Kiefmann M, Meier-Ewert S, O’Brien J, Lehrach H, Bachellerie JP, Brosius J. RNomics: an experimental approach that identifies 201 candidates for novel, small, non-messenger RNAs in mouse. *EMBO J* 2001, 20:2943–2953.

170. Vitali P, Basuuk E, Le Meur E, Bertrand E, Muscatelli F, Cavaillé J, Hüttenhofer A. ADAR2-mediated editing of RNA substrates in the nucleolus is inhibited by C/D small nucleolar RNAs. *J Cell Biol* 2005, 169:745–753.

171. Helm M, Giegé R, Florentz C. A Watson-Crick base-pair-disrupting methyl group (m1A9) is sufficient for cloverleaf folding of human mitochondrial tRNALys. *Biochemistry* 1999, 38:13338–13346.

172. Lu L, Yi C, Jian X, Zheng G, He C. Structure determination of DNA methylation lesions N1-meA and N3-meC in duplex DNA using a cross-linked protein-DNA system. *Nucleic Acids Res* 2010, 38:4415–4425.

173. Hofer T, Badouard C, Bajak E, Ravanat JL, Mattsson A, Cotgreave IA. Hydrogen peroxide causes greater oxidation in cellular RNA than in DNA. *Biol Chem* 2005, 386:333–337.

174. Hudson BH, Zaher HS. O6-Methylguanosine leads to position-dependent effects on ribosome speed and fidelity. *RNA* 2015, 21:1648–1659.

175. Wurtmann EJ, Wolin SL. RNA under attack: cellular handling of RNA damage. *Crit Rev Biochem Mol Biol* 2009, 44:34–49.

176. Calabretta A, Küpfer PA, Leumann CJ. The effect of RNA base lesions on mRNA translation. *Nucleic Acids Res* 2015, 43:4713–4720.

177. Simms CL, Hudson BH, Mosior JW, Rangwala AS, Zaher HS. An active role for the ribosome in determining the fate of oxidized mRNA. *Cell Rep* 2014, 9:1256–1264.

178. Liu N, Parisien M, Dai Q, Zheng G, He C, Pan T. Probing N6-methyladenosine RNA modification status at single nucleotide resolution in mRNA and long noncoding RNA. *RNA* 2013, 19:1848–1856.